Nifty
Sensex
:
:
20267.90
67481.19
134.75 (0.67%)
492.75 (0.74%)

Pharmaceuticals & Drugs - Global

Rating :
73/99

BSE: 524742 | NSE: CAPLIPOINT

1294.45
01-Dec-2023
  • Open
  • High
  • Low
  • Previous Close
  •  1261.30
  •  1310.00
  •  1259.60
  •  1255.00
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  178641
  •  2303.00
  •  1350.00
  •  575.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 9,819.52
  • 23.50
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 9,255.51
  • 0.35%
  • 4.74

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 70.63%
  • 1.77%
  • 18.31%
  • FII
  • DII
  • Others
  • 3.08%
  • 0.19%
  • 6.02%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 17.72
  • 11.39

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 13.70
  • 6.32

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 16.34
  • 15.81

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 19.85
  • 17.65
  • 18.47

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 7.95
  • 4.07
  • 3.87

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.97
  • 11.67
  • 12.47

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 23
Sep 22
Var%
Jun 23
Jun 22
Var%
Mar 23
Mar 22
Var%
Dec 22
Dec 21
Var%
Net Sales
410.06
359.05
14.21%
395.32
346.33
14.15%
389.28
339.24
14.75%
372.07
326.20
14.06%
Expenses
272.66
253.47
7.57%
268.79
244.15
10.09%
265.35
239.30
10.89%
262.70
225.24
16.63%
EBITDA
137.40
105.58
30.14%
126.53
102.18
23.83%
123.93
99.94
24.00%
109.37
100.96
8.33%
EBIDTM
33.51%
29.41%
32.01%
29.50%
31.84%
29.46%
29.39%
30.95%
Other Income
20.43
16.48
23.97%
12.04
13.94
-13.63%
11.40
11.51
-0.96%
14.15
9.54
48.32%
Interest
0.18
0.14
28.57%
0.28
0.06
366.67%
0.23
0.08
187.50%
0.36
0.14
157.14%
Depreciation
11.76
11.46
2.62%
11.38
10.97
3.74%
11.13
11.45
-2.79%
11.43
11.70
-2.31%
PBT
145.89
110.46
32.07%
126.91
105.09
20.76%
123.97
99.92
24.07%
111.73
98.66
13.25%
Tax
29.86
18.42
62.11%
22.76
18.78
21.19%
22.81
19.09
19.49%
14.35
19.38
-25.95%
PAT
116.03
92.04
26.06%
104.15
86.31
20.67%
101.16
80.83
25.15%
97.38
79.28
22.83%
PATM
28.30%
25.63%
26.35%
24.92%
25.99%
23.83%
26.17%
24.30%
EPS
15.12
12.09
25.06%
13.62
11.21
21.50%
13.45
10.43
28.95%
12.84
9.89
29.83%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Jun 15
Jun 14
Net Sales
1,566.73
1,466.73
1,269.41
1,061.29
863.20
648.69
539.84
401.65
238.72
251.77
173.09
Net Sales Growth
14.29%
15.54%
19.61%
22.95%
33.07%
20.16%
34.41%
68.25%
-5.18%
45.46%
 
Cost Of Goods Sold
683.20
663.21
557.51
471.74
413.16
288.78
238.18
184.93
121.16
135.62
102.58
Gross Profit
883.53
803.52
711.90
589.55
450.04
359.91
301.66
216.72
117.56
116.15
70.50
GP Margin
56.39%
54.78%
56.08%
55.55%
52.14%
55.48%
55.88%
53.96%
49.25%
46.13%
40.73%
Total Expenditure
1,069.50
1,026.21
874.88
737.04
603.13
416.84
344.52
276.84
174.51
192.06
136.90
Power & Fuel Cost
-
25.53
21.40
16.36
14.81
13.76
10.98
9.91
7.56
8.61
3.07
% Of Sales
-
1.74%
1.69%
1.54%
1.72%
2.12%
2.03%
2.47%
3.17%
3.42%
1.77%
Employee Cost
-
136.12
114.74
101.97
67.15
45.58
37.61
29.71
17.92
18.24
12.63
% Of Sales
-
9.28%
9.04%
9.61%
7.78%
7.03%
6.97%
7.40%
7.51%
7.24%
7.30%
Manufacturing Exp.
-
90.99
82.01
69.85
68.23
43.49
37.11
28.56
14.33
16.04
7.42
% Of Sales
-
6.20%
6.46%
6.58%
7.90%
6.70%
6.87%
7.11%
6.00%
6.37%
4.29%
General & Admin Exp.
-
62.98
49.16
38.53
25.50
20.82
12.27
13.78
8.15
7.97
6.54
% Of Sales
-
4.29%
3.87%
3.63%
2.95%
3.21%
2.27%
3.43%
3.41%
3.17%
3.78%
Selling & Distn. Exp.
-
18.78
27.52
18.03
9.95
2.08
5.92
9.41
2.29
2.85
1.46
% Of Sales
-
1.28%
2.17%
1.70%
1.15%
0.32%
1.10%
2.34%
0.96%
1.13%
0.84%
Miscellaneous Exp.
-
28.60
22.54
20.56
4.33
2.33
2.45
0.55
3.10
2.72
1.46
% Of Sales
-
1.95%
1.78%
1.94%
0.50%
0.36%
0.45%
0.14%
1.30%
1.08%
1.84%
EBITDA
497.23
440.52
394.53
324.25
260.07
231.85
195.32
124.81
64.21
59.71
36.19
EBITDA Margin
31.74%
30.03%
31.08%
30.55%
30.13%
35.74%
36.18%
31.07%
26.90%
23.72%
20.91%
Other Income
58.02
56.52
38.89
27.93
41.33
19.03
12.67
9.96
3.66
3.03
3.72
Interest
1.05
0.78
0.70
1.59
0.32
0.58
0.61
0.52
0.34
0.97
0.68
Depreciation
45.70
44.99
46.90
36.97
31.62
23.43
19.00
13.30
7.48
8.38
3.54
PBT
508.50
451.27
385.82
313.62
269.46
226.88
188.38
120.95
60.05
53.39
35.69
Tax
89.78
74.36
77.37
62.19
54.38
50.32
43.74
25.44
14.28
12.26
9.76
Tax Rate
17.66%
16.48%
20.05%
19.83%
20.18%
22.18%
23.22%
21.03%
23.78%
22.96%
27.35%
PAT
418.72
376.26
299.84
242.27
215.00
176.56
144.78
95.61
45.77
41.04
25.85
PAT before Minority Interest
417.61
376.99
308.45
251.43
215.08
176.56
144.63
95.50
45.77
41.13
25.93
Minority Interest
-1.11
-0.73
-8.61
-9.16
-0.08
0.00
0.15
0.11
0.00
-0.09
-0.08
PAT Margin
26.73%
25.65%
23.62%
22.83%
24.91%
27.22%
26.82%
23.80%
19.17%
16.30%
14.93%
PAT Growth
23.71%
25.49%
23.76%
12.68%
21.77%
21.95%
51.43%
108.89%
11.53%
58.76%
 
EPS
55.17
49.57
39.50
31.92
28.33
23.26
19.08
12.60
6.03
5.41
3.41

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Jun 15
Jun 14
Shareholder's Funds
1,880.48
1,483.93
1,185.83
947.91
632.91
363.83
224.76
128.14
93.19
61.74
Share Capital
89.76
89.74
89.71
89.71
51.05
15.12
15.12
15.11
15.11
15.11
Total Reserves
1,775.35
1,378.74
1,081.33
848.76
575.01
345.42
209.56
111.40
78.08
46.63
Non-Current Liabilities
2.30
12.55
17.39
24.86
23.42
27.86
19.90
13.69
10.39
10.42
Secured Loans
0.00
0.00
0.00
0.02
0.29
0.32
0.48
0.73
0.88
2.07
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Provisions
7.78
8.48
5.69
5.23
0.13
0.00
0.40
1.63
0.82
0.81
Current Liabilities
268.00
207.68
142.85
144.32
86.11
108.67
113.36
125.04
124.97
107.58
Trade Payables
164.37
155.94
88.50
64.14
60.47
94.23
78.60
55.71
41.56
31.50
Other Current Liabilities
99.94
48.68
51.87
79.28
24.20
13.86
33.09
60.39
72.11
66.42
Short Term Borrowings
3.41
0.50
0.00
0.00
0.00
0.00
0.00
0.00
0.05
0.05
Short Term Provisions
0.28
2.56
2.48
0.91
1.44
0.58
1.67
8.94
11.25
9.60
Total Liabilities
2,177.57
1,730.11
1,363.61
1,125.75
742.52
500.45
358.38
267.14
228.82
179.92
Net Block
279.81
286.57
305.34
272.50
226.84
169.48
151.83
144.23
113.13
102.24
Gross Block
480.32
445.74
422.58
354.79
271.51
231.79
195.15
180.76
142.71
123.06
Accumulated Depreciation
200.51
159.17
117.24
82.29
44.67
62.31
43.31
36.53
29.58
20.82
Non Current Assets
623.11
432.29
349.04
303.23
248.83
196.34
179.16
148.61
146.95
131.30
Capital Work in Progress
220.71
17.73
13.88
20.12
9.70
15.29
3.42
0.23
30.63
24.54
Non Current Investment
70.52
37.01
0.66
0.56
0.33
0.33
13.24
0.44
0.45
0.44
Long Term Loans & Adv.
51.68
89.90
7.92
10.05
11.95
11.23
10.67
3.71
2.75
3.67
Other Non Current Assets
0.39
1.08
21.24
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
1,554.46
1,297.82
1,014.57
822.53
493.69
304.11
179.22
118.53
81.87
48.61
Current Investments
159.17
51.97
10.54
60.23
69.62
46.34
4.20
0.00
0.00
0.00
Inventories
288.22
227.31
179.01
238.23
37.45
28.46
22.29
18.81
13.66
9.79
Sundry Debtors
394.06
317.05
279.36
228.96
159.81
125.88
33.02
7.95
5.66
0.09
Cash & Bank
493.48
462.99
438.33
223.43
152.99
79.28
93.07
68.10
45.37
26.82
Other Current Assets
219.53
17.28
20.25
14.87
73.83
24.16
26.63
23.67
17.18
11.90
Short Term Loans & Adv.
192.21
221.22
87.08
56.81
64.61
17.28
19.31
12.58
11.08
8.16
Net Current Assets
1,286.46
1,090.14
871.72
678.21
407.58
195.44
65.86
-6.51
-43.10
-58.97
Total Assets
2,177.57
1,730.11
1,363.61
1,125.76
742.52
500.45
358.38
267.14
228.82
179.91

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Jun 15
Jun 14
Cash From Operating Activity
271.37
336.73
268.61
44.68
83.42
66.49
67.61
42.40
49.88
59.83
PBT
451.35
385.82
313.62
269.46
226.88
188.38
120.95
60.05
53.39
35.69
Adjustment
11.77
30.44
23.09
7.09
19.12
14.84
8.61
3.87
6.21
2.14
Changes in Working Capital
-103.75
1.96
-1.96
-177.11
-120.06
-100.38
-38.39
-5.13
1.96
29.32
Cash after chg. in Working capital
359.37
418.22
334.75
99.44
125.94
102.84
91.16
58.78
61.56
67.15
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-88.00
-81.49
-66.14
-54.76
-42.51
-36.35
-23.55
-16.38
-11.67
-7.32
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-217.58
-376.77
-29.44
-54.50
-100.46
-69.02
-36.11
-5.72
-22.66
-43.89
Net Fixed Assets
-56.57
-3.66
-35.46
-43.65
58.45
-48.43
-19.56
-7.66
-25.72
-48.50
Net Investments
-169.44
-115.52
46.59
-27.53
-120.03
-29.43
-17.35
0.01
-0.90
0.75
Others
8.43
-257.59
-40.57
16.68
-38.88
8.84
0.80
1.93
3.96
3.86
Cash from Financing Activity
-28.17
-40.68
-23.98
79.77
89.79
-11.60
-6.74
-13.95
-8.67
-5.96
Net Cash Inflow / Outflow
25.62
-80.72
215.19
69.94
72.76
-14.13
24.76
22.73
18.55
9.99
Opening Cash & Equivalents
150.76
231.57
220.77
150.65
77.17
91.31
66.55
45.37
26.82
16.84
Closing Cash & Equivalent
177.56
150.76
435.72
220.77
150.65
77.17
91.31
68.10
45.37
26.82

Financial Ratios

Consolidated /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Jun 15
Jun 14
Book Value (Rs.)
235.91
183.89
144.94
114.21
78.03
47.69
29.73
16.25
11.84
7.68
ROA
19.29%
19.94%
20.20%
23.02%
28.41%
33.68%
30.54%
18.46%
20.12%
16.48%
ROE
23.68%
24.77%
25.65%
29.58%
37.14%
49.43%
54.97%
43.13%
55.78%
53.24%
ROCE
26.85%
28.77%
28.82%
33.35%
45.59%
64.08%
69.03%
55.41%
71.11%
68.99%
Fixed Asset Turnover
3.17
2.92
2.73
2.76
2.58
2.53
2.14
1.48
1.89
2.00
Receivable days
88.48
85.74
87.41
82.19
80.37
53.72
18.62
10.40
4.17
1.00
Inventory Days
64.15
58.42
71.75
58.28
18.54
17.16
18.68
24.83
17.00
21.31
Payable days
88.14
80.02
59.05
28.33
65.76
89.68
88.17
103.48
69.75
79.69
Cash Conversion Cycle
64.48
64.14
100.11
112.15
33.15
-18.80
-50.88
-68.24
-48.58
-57.39
Total Debt/Equity
0.00
0.00
0.01
0.04
0.00
0.00
0.00
0.02
0.02
0.06
Interest Cover
579.65
552.17
198.25
843.86
391.22
309.72
235.08
179.35
56.11
53.29

News Update:


  • Caplin Point Lab - Quarterly Results
    9th Nov 2023, 12:43 PM

    Read More
  • Caplin Point Laboratories’ arm gets USFDA’s final approval for Norepinephrine Bitartrate Injection
    20th Sep 2023, 14:12 PM

    Norepinephrine Bitartrate Injection is used for restoration of blood pressure in adult patients with acute hypotensive states

    Read More
  • Caplin Point Laboratories’ arm gets EIR from USFDA for Chennai unit
    4th Sep 2023, 12:42 PM

    The unit underwent an inspection from USFDA during May 22- May 31

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.